A Phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infectionClinical Trial Published on 2023-01-012023-06-12 Journal: Journal of medical virology [Category] B형 간염, Fulltext, [키워드] Antiviral effect Chronic Hepatitis B HBV DNA HBV infection hepatitis B surface antigen ledipasvir nucleos(t)ide analogues quantitative HBV surface antigen sofosbuvir viral hepatitis b [DOI] 10.1002/jmv.28105 PMC 바로가기 [Article Type] Clinical Trial
SARS-CoV-2 infects human brain organoids causing cell death and loss of synapses that can be rescued by treatment with SofosbuvirArticle Published on 2022-11-032022-11-15 Journal: PLoS Biology [Category] SARS, 치료제, [키워드] accompanied Affect alleviate alteration Antiviral antivirals Brain brain organoid brain organoids cell death cells cellular coronavirus 2 coronavirus disease cortical COVID-19 death determine drug excitatory food infect inhibit SARS-CoV-2 neurological manifestation Neurological symptoms neuronal neurons Newborn pandemic phenotype promote replicate Replication rescued respiratory respiratory illnesses SARS-CoV-2 sofosbuvir Treatment underlie variety WHO World Health Organization [DOI] 10.1371/journal.pbio.3001845 PMC 바로가기
Inhibition of Viral RNA-Dependent RNA Polymerases by Nucleoside Inhibitors: An Illustration of the Unity and Diversity of MechanismsReview Published on 2022-10-212023-07-10 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), [키워드] COVID-19 hepatitis C molnupiravir nucleoside analog RdRP Remdesivir RNA virus SARS-CoV-2 sofosbuvir Transcription [DOI] 10.3390/ijms232012649 PMC 바로가기 [Article Type] Review
Structural insight into the binding interactions of NTPs and nucleotide analogues to RNA dependent RNA polymerase of SARS-CoV-2Article Published on 2022-10-012023-07-06 Journal: Journal of biomolecular structure & dynamics [Category] COVID19(2023년), [키워드] Favipiravir Galidesivir Remdesivir SARS-CoV-2 sofosbuvir [DOI] 10.1080/07391102.2021.1894985
RP-HPLC Method Development, Validation, and Drug Repurposing of Sofosbuvir Pharmaceutical Dosage Form: A Multidimensional StudyResearch article Published on 2022-09-012022-10-05 Journal: Environmental research [Category] COVID19(2023년), SARS, 신약개발, [키워드] Accuracy Agilent binding can be used carried Cell Chromatograph clinical trial complex component correlation coefficient demonstrated Detector development dosage drug Dynamics effective experiment forms high affinity hydrogen bonds Infection injected interacting residue less linear liquid methanol molecular docking Nsp12 occurred parameter parameters pharmaceutical Phenomenex phosphoric acid Photodiode Precision pump quantification ranged repurposing sofosbuvir specificity Standard deviation temperature thresholds treating COVID-19 USA validation was used [DOI] 10.1016/j.envres.2022.113282 [Article Type] Research article
Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessmentdaclatasvir와 Sofosbuvir 및 COVID-19 환자의 결과: GRADE 평가를 통한 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-07-012022-09-11 Journal: Postgraduate medical journal [Category] 임상, [키워드] Admission certainty of evidence chance clinical clinical pharmacology clinical recovery clinically control group Controlled trial COVID-19 daclatasvir database databases death defined estimate evaluate the effect ICU ICU admission IMV inception increase in Infectious diseases intensive care intensive care unit internal medicine intervention group Invasive mechanical ventilation lower mortality Meta-analysis moderate Mortality mortality rate outcome Patient patients with COVID-19 performed Primary outcome randomised controlled trial reduce mortality rate reduced reported risk ratio risk ratios risk reduction RRs secondary outcome Secondary outcomes sofosbuvir sofosbuvir/daclatasvir Standard of care systematic literature search systematic review Virology [DOI] 10.1136/postgradmedj-2021-140287 PMC 바로가기 [Article Type] Meta-Analysis
COVID-19 After Treatment With Direct-acting Antivirals for HCV Infection and Decompensated Cirrhosis: A Case ReportHCV 감염 및 대상성 간경변증에 대한 직접 작용 항바이러스제 치료 후 COVID-19: 증례 보고Case Reports Published on 2022-07-012022-09-11 Journal: In vivo (Athens, Greece) [Category] 치료제, [키워드] Admission Cardiac arrest cirrhosis Combination combination therapy combination treatment coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pneumonia decompensated cirrhosis. diagnosed direct-acting antiviral Direct-acting antivirals discharge discharged eradication Exacerbation HCV hepatitis C hepatitis C virus hospital immunological changes IMPROVE individuals infected individuals Infection inhibitor interferon Liver function long term male NS5A NS5B occurred Occurrence Patient performed Pneumonia polymerase Prevent report RNA SARS-CoV-2 severe COVID-19 sofosbuvir sustained SVR the patient Treatment undetectable velpatasvir virological response with COVID-19 [DOI] 10.21873/invivo.12923 PMC 바로가기 [Article Type] Case Reports
Dual targeting of RdRps of SARS-CoV-2 and the mucormycosis-causing fungus: an in silico perspectiveSARS-CoV-2의 RdRps와 점막진균증 유발 곰팡이의 이중 표적화: 실리코 관점에서Article Published on 2022-07-012022-09-11 Journal: Future Microbiology [Category] Coronavirus, COVID19(2023년), SARS, 신약개발, 치료제, [키워드] average binding affinity calculated comparable Compound Computational drug computational drug design docking drug Drug repurposing Galidesivir GTP IDX-184 in silico inhibitor inhibitors molecular docking molecular dynamics Molecular dynamics simulation Mucormycosis nucleotide nucleotide inhibitors. other compound other compounds Perspective physiological nucleotide present RdRP RdRps Remdesivir reported Rhizopus ribavirin SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2 RdRp Setrobuvir sofosbuvir the SARS-CoV-2 [DOI] 10.2217/fmb-2022-0083 PMC 바로가기 [Article Type] Article
Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir직접 작용 항바이러스제 시메프레비르 및 소포스부비르의 정량 분석을 위한 다양한 분광광도법 적용Article Published on 2022-05-052022-09-11 Journal: Spectrochimica acta. Part A, Molecular and biomole [Category] COVID19(2023년), SARS, 치료제, [키워드] absorbance absorbance value acting analyzed antiviral drug antiviral drugs application applied approved Combination COVID-19 COVID-19 patients direct method direct-acting drug HCV Hepatitis hepatitis C Infection investigated Laboratory mixed form Quantitative analysis replication mechanism report SARS-CoV-2 Simeprevir similarities similarity sofosbuvir Spectrophotometry suggested Tablet tablets Treatment [DOI] 10.1016/j.saa.2022.121012 PMC 바로가기 [Article Type] Article
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19초기 경증 내지 중등도의 COVID-19 환자 치료를 위한 소포스부비르/벨파타스비르 조합의 효능 및 안전성Multicenter Study Published on 2022-04-062022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료법, 치료제, [키워드] Antiviral case-control study clearance clinical outcomes Combination conducted Control control group COVID-19 died Disease progression effective evaluated faster HCV Health health problem Infection Intensive median Mild Moderate COVID-19 multicenter nasal swabs once daily one patient oxygen Patient patients PCR performed prevent disease progression primary endpoint RdRP RdRp inhibitor Replication required RNA-dependent RNA polymerase Safe SARS-CoV-2 SARS-CoV-2 clearance SARS-COV-2 infection secondary endpoint Side effect sofosbuvir standard care Swab Tablet the patient treat treated Treatment Vaccines velpatasvir Ventilation viral clearance [DOI] 10.1038/s41598-022-09741-5 PMC 바로가기 [Article Type] Multicenter Study